Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-1|1|237|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-2|1|297|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|metastatic,MPATH: 551 - sarcoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-3|1|317|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-4|1|319|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-5|1|322|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-6|1|339|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-7|1|340|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-8|1|343|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-9|1|347|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-10|1|359|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-11|1|365|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-12|1|384|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-13|1|389|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-14|1|400|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-15|1|400|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-16|1|405|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-17|1|418|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-18|1|424|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-19|1|425|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-20|1|426|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|metastatic,MPATH: 218 - neoplasm|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-21|1|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-22|1|427|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-23|1|427|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-24|1|428|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-25|1|428|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-26|1|442|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-27|1|442|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-28|1|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-29|1|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-30|1|477|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-31|1|480|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-32|1|480|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-33|1|482|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-34|1|491|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-35|1|511|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-36|1|519|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-37|1|527|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-38|1|583|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-39|1|587|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-40|1|587|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-41|1|598|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-42|1|601|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-43|1|602|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-44|1|635|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-45|1|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-46|1|643|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-47|1|664|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-48|1|691|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-49|1|695|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-13-1|NEf-Gy 1.2,6/87|1|92|neutrons C-252|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-1-50|1|699|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-1|2|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-2|2|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-3|2|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-4|2|407|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-5|2|427|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-6|2|455|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-7|2|489|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-8|2|539|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-9|2|573|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-10|2|629|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-11|2|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-12|2|637|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-13|2|639|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-14|2|684|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-15|2|686|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-16|2|688|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|metastatic lung tumour,MPATH: 446 - squamous cell carcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-17|2|692|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-18|2|699|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-19|2|699|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-20|2|700|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-21|2|700|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-22|2|701|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-23|2|701|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-24|2|712|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-25|2|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-26|2|723|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-27|2|723|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-28|2|749|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-29|2|754|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-30|2|761|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-31|2|761|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-32|2|762|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-33|2|762|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-34|2|766|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-35|2|768|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-36|2|769|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-37|2|789|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-38|2|819|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-39|2|839|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-40|2|840|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-41|2|845|Other deterministic changes|Lower respiratory system|n/a|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-42|2|854|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-43|2|875|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-44|2|887|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-45|2|894|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-46|2|910|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-47|2|910|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-48|2|929|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-49|2|938|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-2|NEf-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-2-50|2|952|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-1|3|455|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-2|3|481|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-3|3|614|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-4|3|622|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-5|3|629|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-6|3|636|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-7|3|638|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-8|3|643|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-9|3|656|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-10|3|720|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-11|3|720|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-12|3|743|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-13|3|747|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-14|3|769|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-15|3|775|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-16|3|775|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-17|3|777|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-18|3|790|Neoplasia benign|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-19|3|796|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-20|3|798|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-21|3|817|Neoplasia malignant|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-22|3|817|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-23|3|831|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-24|3|833|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-25|3|835|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-26|3|838|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-27|3|863|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-28|3|875|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-29|3|876|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-30|3|877|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-31|3|877|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-32|3|877|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-33|3|882|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-34|3|882|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-35|3|882|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-36|3|894|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-37|3|922|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-38|3|925|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-39|3|940|Neoplasia unclassified|Central nervous system among nervous system|benign|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-40|3|943|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-41|3|943|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-42|3|952|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-43|3|953|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-44|3|958|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-45|3|958|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-46|3|965|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-47|3|966|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-48|3|966|Other deterministic changes|Lower respiratory system|n/a|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-49|3|972|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-3|NEm-PC500-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-3-50|3|972|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-1|4|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-2|4|532|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-3|4|583|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-4|4|589|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-5|4|604|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-6|4|609|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 551 - sarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-7|4|622|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-8|4|635|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-9|4|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-10|4|670|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-11|4|695|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-12|4|700|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-13|4|700|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-14|4|723|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-15|4|723|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-16|4|737|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-17|4|758|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-18|4|766|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-19|4|791|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-20|4|798|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-21|4|831|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-22|4|876|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-23|4|887|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-24|4|901|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-25|4|923|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-26|4|923|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-27|4|924|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-28|4|924|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-1|4|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-2|4|532|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-3|4|583|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-4|4|589|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-5|4|604|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-6|4|609|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 551 - sarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-7|4|622|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-8|4|635|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-9|4|644|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-10|4|670|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-11|4|695|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-12|4|700|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-13|4|700|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-14|4|723|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-15|4|723|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-16|4|737|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-17|4|758|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-18|4|766|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-19|4|791|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-20|4|798|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-21|4|831|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-22|4|876|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-23|4|887|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-24|4|901|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-25|4|923|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-26|4|923|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-27|4|924|Other deterministic changes|Lower respiratory system|n/a|
2-13-4|NEf-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-4-28|4|924|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-1|5|264|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-2|5|414|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-3|5|473|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-4|5|587|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-5|5|591|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-6|5|635|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-7|5|663|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-8|5|712|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-9|5|719|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-10|5|743|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-11|5|758|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-12|5|759|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-13|5|806|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-14|5|818|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-15|5|839|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-16|5|840|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-17|5|845|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-18|5|845|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-19|5|869|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-20|5|894|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-21|5|915|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-22|5|929|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-23|5|936|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-24|5|939|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-5|NEm-PC500BN-Gy 0,6/87|1|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-25|5|952|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-1|5|264|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-2|5|414|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-3|5|473|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-4|5|587|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-5|5|591|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-6|5|635|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-7|5|663|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-8|5|712|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-9|5|719|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-10|5|743|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-11|5|758|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-12|5|759|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-13|5|806|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-14|5|818|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-15|5|839|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-16|5|840|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-17|5|845|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-18|5|845|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-19|5|869|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-20|5|894|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-21|5|915|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-22|5|929|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-23|5|936|Other deterministic changes|Lower respiratory system|n/a|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-24|5|939|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-5|NEm-PC500BN-Gy 0,6/87|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-5-25|5|952|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-1|6|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-2|6|333|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-3|6|392|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-4|6|393|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-5|6|412|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-6|6|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-7|6|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-8|6|419|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-9|6|457|Neoplasia malignant|Bone among musculo-skeletal system diseases|benign|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-10|6|467|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-11|6|476|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-12|6|480|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-13|6|480|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-14|6|481|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-15|6|481|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-16|6|494|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-17|6|507|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-18|6|510|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-19|6|510|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-20|6|513|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-21|6|518|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-22|6|518|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-23|6|546|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-24|6|547|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-25|6|548|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-26|6|573|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 354 - cholangiocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-27|6|583|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-28|6|584|Neoplasia malignant|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-29|6|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-30|6|602|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-31|6|611|Neoplasia malignant|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-32|6|637|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-33|6|638|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-34|6|645|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-35|6|652|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-36|6|654|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-37|6|671|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-38|6|679|Hyperplastic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-39|6|679|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-40|6|688|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-41|6|691|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-42|6|695|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-43|6|699|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-44|6|719|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-45|6|742|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-46|6|744|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-47|6|749|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-48|6|750|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-49|6|798|Neoplasia benign|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-50|6|817|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-1|6|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-2|6|333|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-3|6|392|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-4|6|393|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-5|6|412|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-6|6|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-7|6|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-8|6|419|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-9|6|457|Neoplasia malignant|Bone among musculo-skeletal system diseases|benign|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-10|6|467|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-11|6|476|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-12|6|480|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-13|6|480|Neoplasia benign|Lower respiratory system,MA: 0000436 - bronchus|,MPATH: 270 - adenoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-14|6|481|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-15|6|481|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-16|6|494|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-17|6|507|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-18|6|510|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-19|6|510|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-20|6|513|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-21|6|518|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-22|6|518|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-23|6|546|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-24|6|547|Other deterministic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-25|6|548|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-26|6|573|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|metastatic,MPATH: 354 - cholangiocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-27|6|583|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-28|6|584|Neoplasia malignant|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-29|6|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-30|6|602|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-31|6|611|Neoplasia malignant|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-32|6|637|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-33|6|638|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-34|6|645|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-35|6|652|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-36|6|654|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-37|6|671|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-38|6|679|Hyperplastic changes|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-39|6|679|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-40|6|688|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-41|6|691|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-42|6|695|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-43|6|699|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-44|6|719|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-45|6|742|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-46|6|744|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-47|6|749|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-48|6|750|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-49|6|798|Neoplasia benign|Lower respiratory system|n/a|
2-13-6|NEf-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-6-50|6|817|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-1|7|52|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-2|7|237|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-3|7|274|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-4|7|274|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-5|7|277|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-6|7|308|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-7|7|317|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-8|7|322|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-9|7|324|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-10|7|332|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 218 - neoplasm|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-11|7|343|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-12|7|354|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-13|7|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-14|7|391|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-15|7|391|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-16|7|393|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-17|7|397|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-18|7|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-19|7|414|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-20|7|427|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-21|7|428|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-22|7|440|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-23|7|475|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-24|7|475|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-25|7|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-26|7|482|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-27|7|487|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-28|7|490|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-29|7|491|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-30|7|491|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-31|7|512|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-32|7|513|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-33|7|542|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-34|7|560|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-35|7|568|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-36|7|569|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-37|7|571|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-38|7|575|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-39|7|580|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-40|7|580|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-41|7|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-42|7|606|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-43|7|608|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-44|7|608|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-45|7|608|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-46|7|637|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-47|7|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-48|7|668|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-49|7|671|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-50|7|700|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-1|7|52|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-2|7|237|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-3|7|274|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 551 - sarcoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-4|7|274|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-5|7|277|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-6|7|308|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-7|7|317|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-8|7|322|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-9|7|324|Neoplasia malignant|Ovary among reproductive system diseases,MA: 0000384 - ovary|metastatic,MPATH: 218 - neoplasm|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-10|7|332|Neoplasia benign|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 218 - neoplasm|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-11|7|343|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-12|7|354|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-13|7|358|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-14|7|391|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-15|7|391|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-16|7|393|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-17|7|397|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-18|7|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-19|7|414|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-20|7|427|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-21|7|428|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-22|7|440|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-23|7|475|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-24|7|475|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-25|7|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-26|7|482|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-27|7|487|Other deterministic changes|Lower respiratory system|n/a|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-28|7|490|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-29|7|491|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-30|7|491|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-31|7|512|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-32|7|513|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-33|7|542|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-34|7|560|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-35|7|568|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-36|7|569|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-37|7|571|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-38|7|575|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-39|7|580|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-40|7|580|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-41|7|591|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-42|7|606|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-43|7|608|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-44|7|608|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-45|7|608|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-46|7|637|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-47|7|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-48|7|668|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-49|7|671|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-7|NEm-PC75-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-7-50|7|700|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-1|8|285|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-2|8|315|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-3|8|329|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-4|8|347|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-5|8|354|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-6|8|392|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-7|8|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-8|8|425|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-9|8|440|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-10|8|453|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-11|8|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-12|8|476|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-13|8|484|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-14|8|488|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-15|8|488|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-16|8|500|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-17|8|501|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-18|8|524|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-19|8|542|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-20|8|568|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-21|8|580|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-22|8|590|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-23|8|596|Neoplasia benign|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-24|8|596|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-25|8|601|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-26|8|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-27|8|608|Neoplasia benign|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-28|8|609|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-29|8|624|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-30|8|629|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-31|8|635|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-32|8|637|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-33|8|637|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-34|8|637|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-35|8|678|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-36|8|681|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-37|8|684|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-38|8|684|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-39|8|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-40|8|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-41|8|702|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-42|8|708|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-43|8|722|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-44|8|722|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-45|8|723|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-46|8|737|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-47|8|747|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-48|8|750|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-49|8|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-13-8|NEm-PC500-Gy 1.2,6/87|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-50|8|807|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-1|8|285|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-2|8|315|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-3|8|329|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-4|8|347|Neoplasia malignant|Spleen and thymus  among haematolymphatic system,MA: 0000141 - spleen|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-5|8|354|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-6|8|392|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-7|8|412|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-8|8|425|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-9|8|440|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-10|8|453|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-11|8|476|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-12|8|476|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-13|8|484|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-14|8|488|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-15|8|488|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-16|8|500|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-17|8|501|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-18|8|524|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-19|8|542|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-20|8|568|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-21|8|580|Other deterministic changes|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-22|8|590|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-23|8|596|Neoplasia benign|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-24|8|596|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-25|8|601|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-26|8|608|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-27|8|608|Neoplasia benign|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-28|8|609|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-29|8|624|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-30|8|629|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-31|8|635|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-32|8|637|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-33|8|637|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-34|8|637|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-35|8|678|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-36|8|681|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-37|8|684|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-38|8|684|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-39|8|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-40|8|685|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-41|8|702|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-42|8|708|Neoplasia malignant|Lower respiratory system|n/a|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-43|8|722|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-44|8|722|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-45|8|723|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-46|8|737|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-47|8|747|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-48|8|750|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-49|8|758|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 335 - hematopoietic/lymphoid malignancies/disorder|
2-13-8|NEm-PC500-Gy 1.2,6/87|2|92|para-dichlorobenzene|500|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-8-50|8|807|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-1|9|9|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-2|9|9|Neoplasia malignant|Lower respiratory system,MA: 0000032 - thoracic cavity|benign,MPATH: 551 - sarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-3|9|12|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-4|9|28|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-5|9|33|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-6|9|40|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-7|9|42|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-8|9|43|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-9|9|43|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-10|9|49|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-11|9|87|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-12|9|491|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-13|9|517|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-14|9|576|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-15|9|736|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-16|9|748|Neoplasia malignant|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-17|9|760|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-18|9|769|Neoplasia malignant|Reproductive system,MA: 0000404 - prostate gland|,MPATH: 268 - adenocarcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-19|9|790|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-20|9|793|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-21|9|805|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-22|9|825|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|metastatic,MPATH: 278 - follicular adenocarcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-23|9|836|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-24|9|836|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-25|9|840|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-26|9|847|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-27|9|852|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-28|9|873|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-29|9|873|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-30|9|907|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-31|9|907|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-32|9|914|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-33|9|916|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-34|9|916|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-35|9|921|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-36|9|921|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-37|9|923|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-38|9|923|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-39|9|930|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-40|9|946|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-41|9|952|Neoplasia malignant|Reproductive system,MA: 0000410 - seminal vesicle|benign,MPATH: 268 - adenocarcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-42|9|953|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-43|9|959|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-44|9|959|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-45|9|962|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-46|9|974|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-47|9|984|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-48|9|1098|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-49|9|1099|Other deterministic changes|Lower respiratory system|n/a|
2-13-9|NEm-TC15-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-9-50|9|1099|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-1|10|34|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-2|10|401|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-3|10|535|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-4|10|575|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-5|10|589|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-6|10|595|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-7|10|636|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-8|10|644|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-9|10|721|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-10|10|756|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-11|10|760|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-12|10|762|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-13|10|809|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-14|10|810|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-15|10|827|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-16|10|832|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-17|10|833|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-18|10|838|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-19|10|846|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-20|10|853|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-21|10|870|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-22|10|874|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-23|10|890|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-24|10|900|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-25|10|917|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-26|10|948|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-27|10|948|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-28|10|953|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-29|10|960|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|15|parts per million|Inhalation|inhaled|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-30|10|969|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-1|10|34|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-2|10|401|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-3|10|535|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-4|10|575|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-5|10|589|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-6|10|595|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-7|10|636|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-8|10|644|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-9|10|721|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-10|10|756|Neoplasia malignant|Lower digestive tract,MA: 0000353 - stomach|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-11|10|760|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-12|10|762|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-13|10|809|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-14|10|810|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-15|10|827|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-16|10|832|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-17|10|833|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-18|10|838|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-19|10|846|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-20|10|853|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-21|10|870|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-22|10|874|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-23|10|890|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-24|10|900|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-25|10|917|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-26|10|948|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-27|10|948|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-28|10|953|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-29|10|960|Other deterministic changes|Lower respiratory system|n/a|
2-13-10|NEm-TC15BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|30 (30 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-10-30|10|969|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-1|11|19|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-2|11|21|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-3|11|24|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-4|11|33|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-5|11|49|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-6|11|56|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-7|11|510|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-8|11|526|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-9|11|535|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-10|11|538|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-11|11|568|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-12|11|674|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-13|11|685|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-14|11|689|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-15|11|705|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-16|11|707|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-17|11|712|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-18|11|734|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-19|11|749|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-20|11|768|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-21|11|775|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-22|11|777|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-23|11|778|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-24|11|809|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|metastatic,MPATH: 408 - soft tissue fibrosarcoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-25|11|838|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-26|11|846|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-27|11|864|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-28|11|871|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-29|11|879|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-30|11|881|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-31|11|899|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-32|11|907|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-33|11|913|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-34|11|923|Inflammation and/or fibrotic diseases|Lower respiratory system,MA: 0000415 - lung|,MPATH: 215 - granulomatous inflammation|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-35|11|927|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-36|11|941|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-37|11|942|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-38|11|944|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-39|11|945|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-40|11|950|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-41|11|957|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-42|11|959|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-43|11|960|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|metastatic,MPATH: 446 - squamous cell carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-44|11|961|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-45|11|968|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-46|11|969|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-47|11|976|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-48|11|987|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-49|11|1092|Other deterministic changes|Lower respiratory system|n/a|
2-13-11|NEm-TC50-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-11-50|11|1100|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-1|12|9|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-2|12|22|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-3|12|456|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-4|12|496|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-5|12|500|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-6|12|559|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-7|12|573|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-8|12|587|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-9|12|601|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-10|12|610|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-11|12|619|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-12|12|636|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-13|12|647|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-14|12|760|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-15|12|767|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-16|12|790|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-17|12|840|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-18|12|878|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-19|12|883|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-20|12|889|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-21|12|906|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-22|12|944|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-23|12|960|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-24|12|966|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|1|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-25|12|970|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-1|12|9|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-2|12|22|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-3|12|456|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-4|12|496|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-5|12|500|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|metastatic,MPATH: 218 - neoplasm|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-6|12|559|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-7|12|573|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-8|12|587|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-9|12|601|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-10|12|610|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-11|12|619|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-12|12|636|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-13|12|647|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-14|12|760|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-15|12|767|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-16|12|790|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-17|12|840|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-18|12|878|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-19|12|883|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-20|12|889|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-21|12|906|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-22|12|944|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-23|12|960|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-24|12|966|Other deterministic changes|Lower respiratory system|n/a|
2-13-12|NEm-TC50BNy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-12-25|12|970|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-1|13|2|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-2|13|22|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-3|13|29|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-4|13|46|Neoplasia malignant|Liver among hepato-pancreatic system diseases,MA: 0000358 - liver|benign,MPATH: 354 - cholangiocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-5|13|49|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-6|13|52|Neoplasia malignant|Liver among hepato-pancreatic system diseases|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-7|13|537|Neoplasia unclassified|Central nervous system among nervous system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-8|13|606|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-9|13|633|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-10|13|654|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-11|13|677|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-12|13|704|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-13|13|769|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-14|13|816|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-15|13|841|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-16|13|843|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-17|13|864|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-18|13|864|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-19|13|871|Other deterministic changes|Lower respiratory system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-20|13|903|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-21|13|908|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-22|13|908|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-23|13|941|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-24|13|947|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-25|13|947|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-26|13|950|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-27|13|950|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-28|13|971|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-13|NEf-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|29 (29 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-13-29|13|992|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-1|14|2|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-2|14|2|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-3|14|34|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-4|14|346|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-5|14|586|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-6|14|596|Neoplasia malignant|Lower digestive tract,MA: 0000054 - peritoneal cavity|metastatic,MPATH: 365 - mesothelioma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-7|14|638|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-8|14|658|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-9|14|690|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-10|14|732|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-11|14|732|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-12|14|791|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-13|14|793|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-14|14|801|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-15|14|812|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-16|14|816|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-17|14|828|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-18|14|838|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-19|14|843|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-20|14|848|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-21|14|857|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-22|14|875|Neoplasia benign|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 218 - neoplasm|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-23|14|907|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-24|14|915|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|metastatic,MPATH: 426 - leiomyosarcoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-25|14|928|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-26|14|936|Other deterministic changes|Lower respiratory system|n/a|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-27|14|954|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-14|NEm-TC150-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|28 (28 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-14-28|14|979|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-1|15|908|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-2|15|3|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-3|15|3|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-4|15|28|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-5|15|487|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-6|15|556|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-7|15|621|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-8|15|621|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-9|15|624|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-10|15|631|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-11|15|638|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-12|15|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-13|15|643|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-14|15|687|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-15|15|712|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-16|15|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-17|15|759|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-18|15|822|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-19|15|842|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-20|15|861|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-21|15|881|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-22|15|927|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-23|15|959|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-24|15|971|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-25|15|982|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-1|15|908|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-2|15|3|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-3|15|3|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-4|15|28|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-5|15|487|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-6|15|556|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-7|15|621|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-8|15|621|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-9|15|624|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-10|15|631|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-11|15|638|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-12|15|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-13|15|643|Other deterministic changes|Lower respiratory system|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-14|15|687|Neoplasia malignant|Bone among musculo-skeletal system diseases|n/a|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-15|15|712|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-16|15|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-17|15|759|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-18|15|822|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-19|15|842|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-20|15|861|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|,MPATH: 428 - rhabdomyosarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-21|15|881|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-22|15|927|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-23|15|959|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-24|15|971|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-15|NEf-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-15-25|15|982|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-1|16|512|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-2|16|549|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-3|16|624|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-4|16|624|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-5|16|638|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-6|16|647|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-7|16|656|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-8|16|658|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-9|16|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-10|16|681|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-11|16|682|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-12|16|684|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-13|16|710|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-14|16|722|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-15|16|724|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-16|16|725|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-17|16|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-18|16|785|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-19|16|785|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-20|16|841|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-21|16|842|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-22|16|861|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-23|16|907|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-24|16|937|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|1|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-25|16|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-1|16|512|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-2|16|549|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-3|16|624|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-4|16|624|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-5|16|638|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-6|16|647|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-7|16|656|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-8|16|658|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-9|16|663|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 446 - squamous cell carcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-10|16|681|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-11|16|682|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-12|16|684|Inflammation and/or fibrotic diseases|Musculo-skeletal system,MA: 0000011 - connective tissue|,MPATH: 212 - inflammation|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-13|16|710|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-14|16|722|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|,MPATH: 268 - adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-15|16|724|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-16|16|725|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-17|16|731|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-18|16|785|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-19|16|785|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-20|16|841|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-21|16|842|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-22|16|861|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-23|16|907|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-24|16|937|Other deterministic changes|Lower respiratory system|n/a|
2-13-16|NEm-TC150BN-Gy 0,6/86|2|93|BNF ß-naphtoflavone|25|milligrams per kg animal|Injection, not specified|inject.|25 (25 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-16-25|16|966|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-1|17|90|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-2|17|212|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-3|17|249|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-4|17|262|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-5|17|294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-6|17|326|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-7|17|350|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-8|17|357|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-9|17|381|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-10|17|385|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-11|17|389|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-12|17|395|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-13|17|405|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-14|17|408|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-15|17|422|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-16|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-17|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-18|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-19|17|450|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-20|17|452|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-21|17|453|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-22|17|463|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-23|17|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-24|17|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-25|17|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-26|17|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-27|17|491|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-28|17|499|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-29|17|500|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-30|17|500|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-31|17|501|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-32|17|514|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-33|17|535|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-34|17|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-35|17|561|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-36|17|568|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-37|17|575|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-38|17|584|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|benign,MPATH: 426 - leiomyosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-39|17|585|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-40|17|586|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-41|17|612|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-42|17|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-43|17|647|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-44|17|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-45|17|654|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-46|17|666|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-47|17|676|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-48|17|681|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-49|17|718|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-50|17|725|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-1|17|90|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-2|17|212|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-3|17|249|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-4|17|262|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-5|17|294|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-6|17|326|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-7|17|350|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-8|17|357|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-9|17|381|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-10|17|385|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-11|17|389|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-12|17|395|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-13|17|405|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-14|17|408|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-15|17|422|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-16|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-17|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-18|17|426|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-19|17|450|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-20|17|452|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-21|17|453|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-22|17|463|Other deterministic changes|Lower respiratory system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-23|17|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-24|17|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-25|17|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-26|17|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-27|17|491|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-28|17|499|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-29|17|500|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-30|17|500|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-31|17|501|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-32|17|514|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-33|17|535|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-34|17|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-35|17|561|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-36|17|568|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-37|17|575|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-38|17|584|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|benign,MPATH: 426 - leiomyosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-39|17|585|Neoplasia malignant|Liver among hepato-pancreatic system diseases|benign|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-40|17|586|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-41|17|612|Neoplasia benign|Integumentary system,MA: 0000146 - skin gland|,MPATH: 219 - adnexal and skin appendage tumor|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-42|17|645|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|benign,MPATH: 513 - Lymphoid neoplasms|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-43|17|647|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-44|17|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-45|17|654|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-46|17|666|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-47|17|676|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-48|17|681|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-49|17|718|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|,MPATH: 278 - follicular adenocarcinoma|
2-13-17|NEf-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-17-50|17|725|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-1|18|90|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-2|18|236|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-3|18|352|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-4|18|375|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-5|18|380|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-6|18|394|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-7|18|395|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-8|18|405|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-9|18|408|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-10|18|415|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-11|18|415|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-12|18|426|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-13|18|444|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-14|18|452|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-15|18|460|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-16|18|463|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-17|18|465|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-18|18|467|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-19|18|494|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-20|18|512|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-21|18|519|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-22|18|519|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-23|18|521|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-24|18|528|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-25|18|528|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-26|18|530|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-27|18|535|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-28|18|536|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-29|18|536|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-30|18|547|Neoplasia systemic|Haematolymphatic system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-31|18|547|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-32|18|548|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-33|18|548|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-34|18|548|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-35|18|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-36|18|568|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-37|18|575|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-38|18|589|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-39|18|603|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-40|18|610|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-41|18|610|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-42|18|612|Neoplasia benign|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-43|18|662|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-44|18|681|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-45|18|690|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-46|18|718|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-47|18|719|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-48|18|739|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-49|18|791|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-50|18|834|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-1|18|90|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-2|18|236|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-3|18|352|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-4|18|375|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-5|18|380|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-6|18|394|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-7|18|395|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-8|18|405|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-9|18|408|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-10|18|415|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-11|18|415|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-12|18|426|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-13|18|444|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-14|18|452|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-15|18|460|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-16|18|463|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-17|18|465|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-18|18|467|Neoplasia malignant|Lower digestive tract,MA: 0000323 - gastrointestinal system|,MPATH: 426 - leiomyosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-19|18|494|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-20|18|512|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-21|18|519|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-22|18|519|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-23|18|521|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-24|18|528|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-25|18|528|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-26|18|530|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-27|18|535|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-28|18|536|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-29|18|536|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-30|18|547|Neoplasia systemic|Haematolymphatic system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-31|18|547|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-32|18|548|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-33|18|548|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-34|18|548|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-35|18|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-36|18|568|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-37|18|575|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-38|18|589|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-39|18|603|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-40|18|610|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-41|18|610|Neoplasia malignant|Bloodvessels among cardiovascular system|benign|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-42|18|612|Neoplasia benign|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-43|18|662|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-44|18|681|Neoplasia malignant|Spleen and thymus  among haematolymphatic system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-45|18|690|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|benign,MPATH: 218 - neoplasm|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-46|18|718|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-47|18|719|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-48|18|739|Neoplasia unclassified|Pituitary gland and epiphysis among endocrine systems,MA: 0000176 - pituitary gland|,MPATH: 218 - neoplasm|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-49|18|791|Other deterministic changes|Lower respiratory system|n/a|
2-13-18|NEm-TC50-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|50|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-18-50|18|834|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-1|19|196|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-2|19|219|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-3|19|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-4|19|308|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-5|19|315|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-6|19|381|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-7|19|394|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-8|19|394|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-9|19|394|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-10|19|426|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-11|19|444|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-12|19|453|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-13|19|460|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-14|19|463|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-15|19|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-16|19|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-17|19|474|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-18|19|477|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-19|19|480|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-20|19|487|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 409 - fibrous histiocytoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-21|19|530|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-22|19|541|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-23|19|548|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-24|19|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-25|19|558|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-26|19|577|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-27|19|577|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-28|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-29|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-30|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-31|19|617|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-32|19|627|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-33|19|631|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-34|19|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-35|19|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-36|19|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-37|19|654|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-38|19|654|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-39|19|666|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-40|19|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-41|19|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-42|19|684|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-43|19|708|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-44|19|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-45|19|711|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-46|19|712|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-47|19|718|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-48|19|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-49|19|726|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-50|19|732|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-1|19|196|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-2|19|219|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-3|19|224|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-4|19|308|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-5|19|315|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-6|19|381|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-7|19|394|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-8|19|394|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-9|19|394|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-10|19|426|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-11|19|444|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-12|19|453|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-13|19|460|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-14|19|463|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-15|19|467|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-16|19|473|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-17|19|474|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-18|19|477|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-19|19|480|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-20|19|487|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 409 - fibrous histiocytoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-21|19|530|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-22|19|541|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-23|19|548|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|metastatic,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-24|19|549|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-25|19|558|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-26|19|577|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-27|19|577|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-28|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-29|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-30|19|604|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-31|19|617|Neoplasia malignant|Other local manifestations and miscellaneus|metastatic|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-32|19|627|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-33|19|631|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-34|19|633|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-35|19|639|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-36|19|652|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-37|19|654|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-38|19|654|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-39|19|666|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|metastatic,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-40|19|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-41|19|682|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-42|19|684|Other deterministic changes|Lower respiratory system|n/a|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-43|19|708|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-44|19|710|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-45|19|711|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 549 - carcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-46|19|712|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-47|19|718|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-48|19|719|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-49|19|726|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-19|NEf-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Female|Young Adult|Lifespan study|2-13-19-50|19|732|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-1|20|289|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-2|20|301|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-3|20|331|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-4|20|350|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-5|20|373|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-6|20|380|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-7|20|394|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-8|20|394|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-9|20|443|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-10|20|453|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-11|20|486|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-12|20|488|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-13|20|498|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-14|20|499|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-15|20|501|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-16|20|528|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-17|20|533|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-18|20|536|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-19|20|536|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-20|20|544|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-21|20|549|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-22|20|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-23|20|556|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-24|20|561|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-25|20|561|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-26|20|568|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-27|20|590|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-28|20|591|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-29|20|591|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-30|20|596|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-31|20|611|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-32|20|612|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-33|20|625|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-34|20|627|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-35|20|645|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-36|20|647|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-37|20|656|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-38|20|664|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-39|20|676|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-40|20|704|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-41|20|705|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-42|20|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-43|20|712|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-44|20|725|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-45|20|726|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-46|20|729|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-47|20|729|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-48|20|738|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-49|20|747|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 242 - hemangiosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|1|92|neutrons fission|1.2|grays|External exposure|Silene|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-50|20|800|Other deterministic changes|Whole body|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-1|20|289|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-2|20|301|Neoplasia malignant|Lower respiratory system,MA: 0000415 - lung|,MPATH: 242 - hemangiosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-3|20|331|Neoplasia malignant|Adrenal gland  among endocrine systems|benign|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-4|20|350|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|metastatic,MPATH: 513 - Lymphoid neoplasms|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-5|20|373|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|metastatic,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-6|20|380|Neoplasia malignant|Musculo-skeletal system,MA: 0000015 - muscle organ|metastatic,MPATH: 428 - rhabdomyosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-7|20|394|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-8|20|394|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-9|20|443|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-10|20|453|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-11|20|486|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-12|20|488|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-13|20|498|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-14|20|499|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-15|20|501|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-16|20|528|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-17|20|533|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-18|20|536|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-19|20|536|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|benign,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-20|20|544|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-21|20|549|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-22|20|549|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|benign,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-23|20|556|Neoplasia malignant|Other local manifestations and miscellaneus,MA: 0000003 - organ system|,MPATH: 408 - soft tissue fibrosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-24|20|561|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-25|20|561|Neoplasia malignant|Nervous system and special sense organs,MA: 0000016 - nervous system|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-26|20|568|Other deterministic changes|Lower respiratory system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-27|20|590|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-28|20|591|Neoplasia malignant|Thyroid and parathyroid glands among endocrine systems,MA: 0000129 - thyroid gland|benign,MPATH: 278 - follicular adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-29|20|591|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-30|20|596|Neoplasia malignant|Other local manifestations and miscellaneus|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-31|20|611|Neoplasia malignant|Bone among musculo-skeletal system diseases|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-32|20|612|Neoplasia malignant|Upper digestive tract,MA: 0000346 - salivary gland|,MPATH: 551 - sarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-33|20|625|Neoplasia malignant|Bloodvessels among cardiovascular system|metastatic|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-34|20|627|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-35|20|645|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-36|20|647|Neoplasia malignant|Bloodvessels among cardiovascular system|n/a|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-37|20|656|Neoplasia malignant|Other local manifestations and miscellaneus|benign|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-38|20|664|Neoplasia malignant|Urinary system,MA: 0002636 - lower urinary tract|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-39|20|676|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-40|20|704|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-41|20|705|Neoplasia malignant|Pancreas among hepato-pancreatic system diseases,MA: 0000120 - pancreas|metastatic,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-42|20|711|Neoplasia systemic|Haematolymphatic system,MA: 0002434 - hematopoietic system|,MPATH: 513 - Lymphoid neoplasms|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-43|20|712|Neoplasia malignant|Mammary gland,MA: 0000145 - mammary gland|benign,MPATH: 268 - adenocarcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-44|20|725|Neoplasia malignant|Integumentary system,MA: 0000151 - skin|,MPATH: 446 - squamous cell carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-45|20|726|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-46|20|729|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-47|20|729|Neoplasia malignant|Adrenal gland  among endocrine systems,MA: 0000116 - adrenal gland|benign,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-48|20|738|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|,MPATH: 549 - carcinoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-49|20|747|Neoplasia malignant|Kidney among urinary system diseases,MA: 0000368 - kidney|metastatic,MPATH: 242 - hemangiosarcoma|
2-13-20|NEm-TC150-Gy 1.2,6/86|2|92|tetrachlorbenzyltoluene|150|milligrams|Inhalation|inhaled|50 (50 in ERA)|Rat|Rat, Sprague-Dawley SPF|Male|Young Adult|Lifespan study|2-13-20-50|20|800|Other deterministic changes|Whole body|n/a|
